scholarly journals Intravitreal triamcinolone for diffuse diabetic macular oedema

2006 ◽  
Vol 90 (9) ◽  
pp. 1079-1080
Author(s):  
A Longo
Keyword(s):  
Macular Oedema ◽  
Diabetic Macular Oedema ◽  
Intravitreal Triamcinolone

scholarly journals Effect of intravitreal Triamcinolone (2mg) on diabetic macular oedema in the pseudophakic patient as primary treatment

2020 ◽  
Vol 11 (3) ◽  
pp. 3533-3539
Author(s):  
Mohammed Qasim Al Nuwaini ◽  
Giyathaldeen T. Neameh ◽  
Mustafa A. Al Zubaidi Md ◽  
Farook M. Albusultan
Keyword(s):  
Visual Acuity ◽  
Intraocular Pressure ◽  
Intravitreal Injection ◽  
Macular Oedema ◽  
Diabetic Macular Oedema ◽  
Visual Outcome ◽  
Primary Treatment ◽  
Macular Thickness ◽  
Central Macular Thickness ◽  
Intravitreal Triamcinolone

Diabetic macular oedema is still a significant cause of vision drop in the diabetic patient with no definitive regime for treatment. This study was on the result of effects of intravitreal injection of (2mg) triamcinolone on central macular thickness measured by OCT, visual acuity and intraocular pressure in pseudophakic eyes with diabetic macular oedema as a primary treatment line followed in six months. This study is a prospective, interventional case study series. It was on patients who received intravitreal injection of Triamcinolone in a single dose of ( 2 mg/0. 05 ml). Central macular thickness by OCT, visual acuity, and intraocular pressure was measured pre-injection and 1,3,6 months after injection. This study was performed in Iraq, Baghdad, Ibn Al-Haitham Teaching Eye Hospital from October 2014 to July 2015. Results showed 25 eyes received intravitreal injection of Triamcinolone Acetoniod with pre-injection central macular thickness 597.9+98.02 µm, visual acuity 1.096+0.61 Log MAR and intraocular pressure of 16.5+ 2.53 mmHg. After six months of follow up on central macular thickness 341.6+163.1 µm, visual acuity was 0.63 + 0.40 Log MAR and IOP was 18. 04+ 5. 63mmHg. This study suggests that intravitreal injection of Triamcinolone in a dose 2mg / 0. 05ml improves both anatomical and visual outcome in 21 eyes (84%) out of 25 pseudophakic eyes with diabetic macular oedema during first six months after injection and an increase in intraocular pressure in 2 eyes (8%). The intraocular pressure was despite the use of anti-glaucoma medications during this period.

scholarly journals Triamcinolone Acetonide for the Treatment of Diabetic Macular Oedema

2010 ◽  
Vol 8 (1) ◽  
pp. 42
Author(s):  
Valentina Sarao ◽  
Daniele Veritti ◽  
Paolo Lanzetta ◽  
◽  
◽  
...  
Keyword(s):  
Triamcinolone Acetonide ◽  
Macular Oedema ◽  
Diabetic Macular Oedema ◽  
Standard Of Care ◽  
Blood Retinal Barrier ◽  
Intravitreal Triamcinolone ◽  
Duration Of Action ◽  
Routes Of Administration ◽  
Severe Visual Loss ◽  
Randomised Controlled

Diabetic macular oedema is a major cause of severe visual loss whose pathogenesis appears to be complex and multifactorial. For many years laser photocoagulation has been the standard of care for the treatment of this condition. Emerging pharmacologic approaches are being evaluated through randomised controlled trials. Triamcinolone acetonide has been proposed as a promising option, due to its well-known anti-inflammatory, anti-permeability and anti-angiogenic properties. Intravitreal delivery allows bypassing of the blood–retinal barrier to achieve a more concentrated dose of steroid in the vitreal cavity for a prolonged time. Intravitreal triamcinolone acetonide is effective in reducing central macular thickness and improving visual acuity, even if the duration of action is often provisional and requires repeated injections. Drug-related and injection-related side effects have been reported; the most common are induced cataract and increased intraocular pressure. To extend the duration of steroid effects and to minimise the risk of complications, alternative routes of administration and extend-release implants are being investigated.

Sign in / Sign up

Export Citation Format

Share Document